Organisation paid for research Program year 2024 Source: CMS Open Payments

Clinical Research Solutions - Jackson

Neither a doctor nor a teaching hospital

Research payments

$304,605

20 payments

Through program year 2024, Clinical Research Solutions - Jackson is reported as receiving $304,605 in research payments, across 20 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $16,294 1
2023 Research $13,811 1
2022 Research $9,183 2
2021 Research $21,263 9
2020 Research $107,821 5
2019 Research $136,233 2

Breakdown

Who paid Research payments · program years 2019–2024
  1. E.R. Squibb & Sons, L.L.C. $290,916 10 payments
  2. Braintree Laboratories, Inc. $13,689 10 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to $133,233 1 payment
  2. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod $77,547 1 payment
  3. Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis $57,845 5 payments
  4. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis $16,294 1 payment
  5. Bli4900-302 $13,689 10 payments
  6. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Stage 3 Liver Fibrosis $3,000 1 payment
  7. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to $2,996 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record